This week it will be an honour for me to attend the Clinical Trials Nexus European Series event as a Keynote speaker and am grateful to Procurement Direct for the invitation to join the event.
#nexusseries #procurementdirect #ctn #clinicaltrials
Clinical Trials Nexus European Series facilitate meaningful interactions and the exchange of information between pharmaceutical, biotechnology and research organisations corporate leaders to accelerate the development of novel therapies to address unmet needs & on-going pandemic. The Pharma and Bio-Tech companies are consistently evolving and new clinical studies, technologies and advancements in care and treatments have augmented the efficiency and at the same time the complexity of clinical trials has increased, with tests being carried out in a highly structured and closely coordinated manner.
Clinical Trials Nexus intends to focus on the global health and clinical trials around Europe, patient recruitment, site selection, real-world data, data integration & Strategy, outsourcing, vendor management, quality (QbD) in Trial Conduct, risk-based monitoring, and other significant topics that play a key role in clinical trials will be addressed along with innovative sessions on new technologies, effective and quality collaborations
Check out the event page:
https://procurementdirect.co.uk/clinical-trials-nexus-europe-2020/
Listen to my Keynote on 26 November at 3pm:
AT a time when clinical research is on the minds of everyone it is rather poignant that my topic is more relevant now than it was when I was originally invited. The Coronavirus Pandemic has got us all considering how to navigate clinical trials and what are the best approaches for patient recruitment and retention. It is my belief that implementing patient engagement from the onset of the trial during trial design could be the beneficial answer.
My Keynote Title:
Patient Engagement within Early Development and Preclinical Phases of clinical research: What, Who, Where, When and Why – A Patients Perspective.
Acknowledgement:
Thank you to Patient Focused Medicine’s Development for supporting my keynote with slides and giving me speaking advice, especially Chi Pakarinen, and also thank you to my fellow group members who I have worked with this last couple of years on the ‘How-To’ project that I will highlight during my keynote.
Then I’ll be chairing a panel discussion at 5pm
COVID-19 is an incredible challenge for patients as impairs their participation/retention in clinical studies. What common strategies should be adopted to mitigate this risk?
TOPICS ON THE AGENDA
EARLY CLINICAL DEVELOPMENT
CRO SELECTION PROCESS
COVID-19: PRESENT AND FUTURE EVALUATION
PATIENT CENTRIC TRIALS
DATA AND TECHNOLOGY
OPERATIONS AND OUTSOURCING
